Search results

• MDAI
  serotonin releasing agent (SSRA) with neglible effects on dopamine and norepinephrine. MDAI was developed by the American medicinal chemist and pharmacologist
  17 KB (2,560 words) - 07:40, 12 October 2023
• A-PVP
  which includes compounds like MDPV, hexen, and a-PHP. It acts as a norepinephrine-dopamine reuptake inhibitor. α-PVP was patented in the 1960s by Boehringer
  24 KB (3,456 words) - 00:08, 3 November 2023
• Ethylphenidate
  dopamine reuptake inhibitor and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters
  18 KB (2,561 words) - 14:02, 16 April 2024
• Mephedrone
  promoting the release of the neurotransmitters serotonin, dopamine, and norepinephrine in the brain.[citation needed] Mephedrone was first synthesized in 1929
  29 KB (3,963 words) - 14:23, 16 April 2024
• 2-Aminoindane
  acts as both a dopamine and norepinephrine releasing agent. This means it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters
  12 KB (1,928 words) - 23:42, 21 April 2024
• Methylone
  Methylone acts as a mixed reuptake inhibitor/releasing agent of serotonin, norepinephrine, and dopamine. These neurotransmitters are thought to be responsible
  19 KB (2,841 words) - 14:21, 16 April 2024
• MDA
  (Ecstasy). As with MDMA, MDA is thought to act primarily as a serotonin-norepinephrine-dopamine reuptake inhibitor and releasing agent.[citation needed] However
  31 KB (4,379 words) - 12:23, 6 May 2024
• 1V-LSD
  likely similar to that of LSD, which acts on serotonin, dopamine, and norepinephrine receptors in the brain. 1V-LSD is a research chemical that appears to
  28 KB (3,658 words) - 15:27, 10 March 2023
• 4F-MPH
  primarily as a dopamine and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of dopamine and norepinephrine neurotransmitters in the
  16 KB (2,465 words) - 15:45, 9 May 2024
• Hexedrone
  most likely acts as both a dopamine and norepinephrine reuptake inhibitor. This allows dopamine and norepinephrine to build up within the brain, resulting
  8 KB (961 words) - 23:45, 21 April 2024
• Desoxypipradrol
  dementia. As with methylphenidate and pipradol, it is thought to act as a norepinephrine-dopamine reuptake inhibitor (NDRI). Of these three piperidines, it is
  19 KB (2,776 words) - 00:39, 1 August 2022
• Tapentadol
  of action, working on both the μ-opioid receptor and also acting as a norepinephrine reuptake inhibitor. Tapentadol is used in the management of moderate
  12 KB (2,182 words) - 23:51, 21 April 2024
• Prolintane
  thought to act primarily as a mild norepinephrine-dopamine reuptake inhibitor. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations
  11 KB (1,751 words) - 20:42, 12 September 2022
• 3-FA
  dopamine and norepinephrine releasing agent, with modest selectivity for serotonin. This means it effectively increases the levels of the norepinephrine and dopamine
  15 KB (2,726 words) - 11:39, 17 February 2024
• Clonidine
  activity on the α2 receptors in the brainstem inhibits the release of norepinephrine (NE), resulting in decreased sympathetic nervous system tone. Clonidine
  22 KB (2,932 words) - 13:49, 16 April 2024
• Cyclazodone
  The mechanism of action involves promoting the release of dopamine and norepinephrine in the brain. Cyclazodone was developed in the 1960s by the American
  19 KB (2,675 words) - 16:54, 31 March 2024
• 3-FEA
  releaser of the monoamine neurotransmitters serotonin, dopamine, and norepinephrine. It has been demonstrated that compared to the unsubstituted ethylamphetamine
  19 KB (3,317 words) - 15:23, 30 July 2022
• Modafinil
  promote dopamine, norepinephrine, histamine, and hypocretin / orexin. Modafinil and its R-enantiomer, armodafinil, increase both norepinephrine (NE) and dopamine
  19 KB (3,104 words) - 11:29, 16 April 2024
• NEP
  serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) with very poor affinity for SERT. This allows dopamine, serotonin and norepinephrine to accumulate
  18 KB (2,677 words) - 06:56, 28 April 2024
• 5-MAPB
  in effect. 5-MAPB is a triple reuptake inhibitor for the monoamines norepinephrine, dopamine and serotonin as well as being an agonist for the 5-HT2A and
  13 KB (2,233 words) - 00:32, 31 December 2022

View (previous 20 | next 20) (20 | 50 | 100 | 250 | 500)